-
1 Comment
Teva Pharmaceutical Industries Limited is currently in a long term downtrend where the price is trading 11.3% below its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.7.
Teva Pharmaceutical Industries Limited's total revenue rose by 11.5% to $4B since the same quarter in the previous year.
Its net income has increased by 37.6% to $150M since the same quarter in the previous year.
Finally, its free cash flow fell by 63.0% to $155M since the same quarter in the previous year.
Based on the above factors, Teva Pharmaceutical Industries Limited gets an overall score of 3/5.
ISIN | US8816242098 |
---|---|
Industry | Drug Manufacturers - Specialty & Generic |
Exchange | F |
CurrencyCode | EUR |
Sector | Healthcare |
Target Price | 11.47 |
---|---|
Market Cap | 14B |
PE Ratio | None |
Beta | 0.72 |
Dividend Yield | None |
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders " chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for TEV.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025